Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

GPCR

Structure Therapeutics Inc ADR

Dec 07 • 04:00PM ET

59.86

Dollar change -0.87
Percentage change -1.43	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.30	Insider Own	8.68%	Shs Outstand	36.59M	Perf Week	7.49%
Market Cap	2.15B	Forward P/E	-	EPS next Y	-0.99	Insider Trans	0.00%	Shs Float	32.79M	Perf Month	-15.31%
Income	-76.69M	PEG	-	EPS next Q	-0.21	Inst Own	81.41%	Short Float / Ratio	8.13% / 2.80	Perf Quarter	113.25%
Sales	0.00M	P/S	-	EPS this Y	83.56%	Inst Trans	-	Short Interest	2.66M	Perf Half Y	76.32%
Book/sh	5.37	P/B	11.14	EPS next Y	-14.74%	ROA	-	Target Price	89.17	Perf Year	-
Cash/sh	5.72	P/C	10.46	EPS next 5Y	-	ROE	-	52W Range	20.80 - 75.02	Perf YTD	130.23%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-39.13%	52W High	-20.20%	Beta	-
Dividend %	-	Quick Ratio	10.45	Sales past 5Y	0.00%	Gross Margin	-	52W Low	187.79%	ATR	4.17
Employees	68	Current Ratio	10.45	Sales Q/Q	-	Oper. Margin	0.00%	RSI (14)	53.56	Volatility	6.57% 8.63%
Optionable	Yes	Debt/Eq	0.02	EPS Q/Q	-48.11%	Profit Margin	-	Rel Volume	0.41	Prev Close	60.73
Shortable	Yes	LT Debt/Eq	0.02	Earnings	Nov 14 AMC	Payout	-	Avg Volume	951.27K	Price	59.86
Recom	1.00	SMA20	8.00%	SMA50	-0.14%	SMA200	63.96%	Volume	391,546	Change	-1.43%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-19-23	Initiated	JMP Securities	Mkt Outperform	$90
Jul-27-23	Initiated	Piper Sandler	Overweight	$58
May-25-23	Resumed	Jefferies	Buy	$34 → $41
Feb-28-23	Initiated	SVB Securities	Outperform	$33
Feb-28-23	Initiated	Jefferies	Buy	$34
Feb-28-23	Initiated	Guggenheim	Buy	$50
Feb-28-23	Initiated	BMO Capital Markets	Outperform	$40

Nov-29-23 02:28PM	If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names (InvestorPlace)
02:30AM	11 Best Young Stocks to Buy and Hold For 20 Years (Insider Monkey)
Nov-27-23 09:50AM	11 Best Upside Stocks To Buy Right Now (Insider Monkey)
Nov-26-23 04:44PM	2 Biotech Stocks That Could Soar in December (Motley Fool)
Nov-14-23 04:10PM	Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
05:20AM	Loading…
Nov-03-23 05:20AM	Should You Still Buy the Nasdaq's Best-Performing October Stocks? (Motley Fool)
Oct-19-23 08:45AM	Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders (PR Newswire)
Oct-06-23 08:45AM	Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why (Zacks)
Oct-02-23 03:48PM	Why Shares of Structure Therapeutics Are Up Monday (Motley Fool) +12.26%
Sep-29-23 04:04PM	Structure Soars 35% As Newcomer Takes On Behemoths Lilly, Novo In Obesity Treatment (Investor's Business Daily) +34.56%
12:50PM	Why Shares of Structure Therapeutics Are Soaring on Friday (Motley Fool)
11:19AM	Structure Stock Soars. Its Obesity Pill Could Challenge Lilly, Novo. (Barrons.com)
10:24AM	Upstart Weight-Loss Drugmaker Jumps 75% on Strong Test Results (Bloomberg)
09:34AM	Newcomer Structure Throws Down The Gauntlet In Obesity Treatment -- Shares Soar 66% (Investor's Business Daily)
07:32AM	Structure Therapeutics Announces $300 Million Private Placement Equity Financing (GlobeNewswire)
07:30AM	Loading…
07:30AM	Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update (GlobeNewswire)
Aug-10-23 04:05PM	Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-03-23 05:32PM	Structure Therapeutics Appoints Ted W. Love, M.D., to Board of Directors (GlobeNewswire)
Jul-16-23 07:00AM	Drugs Like Ozempic Created a Gold Rush. These Drugmakers Want In. (The Wall Street Journal)
Jun-27-23 02:10PM	Eli Lilly, Pfizer, and Others Are Working on Weight-Loss Pills. What to Know. (Barrons.com) +8.16%
01:35PM	Lilly, Pfizer and Others Are Working on Obesity Pills. What to Know. (Barrons.com)
08:12AM	Pfizer Makes a Call on Obesity Pill. Investors Arent Happy. (Barrons.com)
Jun-26-23 09:05PM	Why Shares of Structure Therapeutics Rose Monday (Motley Fool) +18.35%
Jun-16-23 08:00AM	This Biotech Is Developing The Next Ozempic. Should You Buy It? (Motley Fool)
Jun-13-23 06:10AM	Institutional investors own a significant stake of 45% in Structure Therapeutics Inc. (NASDAQ:GPCR) (Simply Wall St.)
Jun-12-23 10:15AM	Buying Shares of These 2 Biotech Stocks Could Be a Brilliant Move in 5 Years (Motley Fool)
Jun-07-23 08:30AM	Structure Therapeutics Announces Poster Presentations of its Oral GLP-1 Receptor Agonist GSBR-1290 at the American Diabetes Association 83rd Scientific Sessions (GlobeNewswire)
May-31-23 04:30PM	Structure Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
May-25-23 04:30PM	Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity (GlobeNewswire) +7.94%
May-18-23 04:30PM	Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference (GlobeNewswire)
04:30PM	Loading…
May-11-23 04:30PM	Structure Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-03-23 06:59AM	Companies Like Structure Therapeutics (NASDAQ:GPCR) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-30-23 04:30PM	Structure Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
Feb-07-23 04:00PM	Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional American Depositary Shares (GlobeNewswire)
Feb-06-23 03:17PM	The Funded: A solar industry company is on deck to complete the 1st major Bay Area tech IPO in more than a year (American City Business Journals)

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GPCR

Structure Therapeutics Inc ADR

Upgrade your FINVIZ experience